Leach OBGYN highlights menopause certification and FDA hormone therapy label update

Dr. Timothy A. Leach and Marybeth Wakefield are drawing attention to their Menopause Society certification and to recent FDA labeling changes for low-dose vaginal estrogen therapies. The update underscores evolving guidance for women managing menopause-related symptoms, including breast cancer survivors.

Why it matters: - Menopause care is often long-term and symptom-specific, so updated information on hormone therapy can shape treatment decisions for many patients. - The FDA label change affects low-dose vaginal estrogen products used for genitourinary syndrome of menopause, a condition that can affect comfort, urinary health, and quality of life. - Better patient education may help women weigh benefits and risks with a provider before starting therapy.

What happened: - Dr. Timothy A. Leach, MD, FACOG, MSCP, and Marybeth Wakefield, RN, MSN, FNP-BC, MSCP, of Dr. Leach OBGYN in Walnut Creek, California, are highlighting their Menopause Society certification. - Both clinicians hold the Menopause Society Certified Practitioner credential. - The practice is also sharing updated information on recent U.S. Food and Drug Administration labeling changes related to hormone therapy. - Dr. Timothy A. Leach said accurate, current information is essential for patients making decisions about hormone therapy. - Dr. Leach said localized vaginal estrogen may be an appropriate treatment option for people with genitourinary symptoms related to low estrogen, based on individual risk assessment and clinical guidelines.

The details: - The Menopause Society Certified Practitioner credential recognizes advanced training and demonstrated knowledge in evidence-based menopause care. - The certification reflects expertise in evaluating and managing perimenopause, menopause, and related midlife health concerns. - The FDA recently updated boxed warning language for low-dose vaginal estrogen therapies indicated for treatment of genitourinary syndrome of menopause. - Genitourinary syndrome of menopause is associated with decreased estrogen levels. - Symptoms may include vaginal dryness, irritation, discomfort with intercourse, urinary urgency, and recurrent urinary tract infections. - The labeling revisions reflect current evidence on the safety profile of localized vaginal estrogen therapy when prescribed for all women, including breast cancer survivors. - Genitourinary syndrome of menopause is common and may significantly affect quality of life. - Symptoms can often be managed with moisturizers, lubricants, topical vaginal therapies, and, when indicated, hormone treatment. - Treatment decisions are based on medical history, symptom severity, and patient preferences. - Marybeth Wakefield said patient education remains central to midlife care. - Wakefield said the goal is to help patients understand the benefits and potential risks of therapy so they can make informed choices with their provider. - Dr. Leach is a board-certified obstetrician-gynecologist and serves as Medical Director of OB GYN at John Muir Medical Center in Walnut Creek. - The practice offers menopause management, minimally invasive surgery, preventive screenings, and general gynecologic care. - New patients are being accepted.

Between the lines: - The message combines clinical credentialing with a regulatory update, signaling an effort to build trust around menopause treatment decisions. - The FDA wording change may reassure some patients and clinicians who have been cautious about local estrogen therapy, especially in higher-risk groups. - The emphasis on individualized risk assessment reflects a more tailored approach to menopause care rather than one-size-fits-all treatment.

What's next: - Dr. Leach OBGYN says it is accepting new patients. - The practice directs patients seeking more information or consultations to its website and office line. - More information is available on the practice website. - The practice also lists social channels on Instagram, Facebook, and YouTube.

The bottom line: - Dr. Leach OBGYN is using its menopause credentials and the FDA update to reinforce that hormone therapy decisions should be guided by current evidence, individualized risk review, and informed patient choice.